Annual EBITDA
-$561.51 M
-$385.84 M-219.64%
30 September 2024
Summary:
Arrowhead Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$561.51 million, with the most recent change of -$385.84 million (-219.64%) on 30 September 2024. During the last 3 years, it has fallen by -$428.93 million (-323.53%). ARWR annual EBITDA is now -955.57% below its all-time high of $65.63 million, reached on 30 September 2019.ARWR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$153.13 M
+$10.97 M+6.69%
30 September 2024
Summary:
Arrowhead Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently -$153.13 million, with the most recent change of +$10.97 million (+6.69%) on 30 September 2024. Over the past year, it has dropped by -$24.07 million (-18.65%). ARWR quarterly EBITDA is now -376.39% below its all-time high of $55.40 million, reached on 31 March 2023.ARWR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$561.51 M
-$53.26 M-10.48%
30 September 2024
Summary:
Arrowhead Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently -$561.51 million, with the most recent change of -$53.26 million (-10.48%) on 30 September 2024. Over the past year, it has dropped by -$293.04 million (-109.15%). ARWR TTM EBITDA is now -955.58% below its all-time high of $65.63 million, reached on 30 September 2019.ARWR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ARWR EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -219.6% | -18.6% | -109.2% |
| 3 y3 years | -323.5% | -152.1% | -228.1% |
| 5 y5 years | -955.6% | -4161.8% | -1225.0% |
ARWR EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -323.5% | at low | -376.4% | +6.7% | -473.9% | at low |
| 5 y | 5 years | -955.6% | at low | -376.4% | +6.7% | -1225.0% | at low |
| alltime | all time | -955.6% | at low | -376.4% | +6.7% | -955.6% | at low |
Arrowhead Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | -$561.51 M(+219.6%) | -$153.13 M(-6.7%) | -$561.51 M(+10.5%) |
| June 2024 | - | -$164.10 M(+42.4%) | -$508.26 M(+15.7%) |
| Mar 2024 | - | -$115.23 M(-10.7%) | -$439.10 M(+63.6%) |
| Dec 2023 | - | -$129.06 M(+29.2%) | -$268.48 M(+52.8%) |
| Sept 2023 | -$175.67 M(+8.2%) | -$99.87 M(+5.2%) | -$175.67 M(+13.1%) |
| June 2023 | - | -$94.95 M(-271.4%) | -$155.30 M(+19.6%) |
| Mar 2023 | - | $55.40 M(-252.8%) | -$129.80 M(-6.1%) |
| Dec 2022 | - | -$36.26 M(-54.4%) | -$138.25 M(-15.1%) |
| Sept 2022 | -$162.29 M(+22.4%) | -$79.50 M(+14.5%) | -$162.74 M(+18.4%) |
| June 2022 | - | -$69.45 M(-247.9%) | -$137.43 M(+40.5%) |
| Mar 2022 | - | $46.96 M(-177.3%) | -$97.85 M(-42.8%) |
| Dec 2021 | - | -$60.75 M(+12.1%) | -$171.12 M(+29.1%) |
| Sept 2021 | -$132.58 M(+52.0%) | -$54.19 M(+81.4%) | -$132.58 M(+4.6%) |
| June 2021 | - | -$29.87 M(+13.5%) | -$126.74 M(+13.9%) |
| Mar 2021 | - | -$26.31 M(+18.5%) | -$111.28 M(+5.1%) |
| Dec 2020 | - | -$22.21 M(-54.1%) | -$105.83 M(+21.3%) |
| Sept 2020 | -$87.22 M(-232.9%) | -$48.34 M(+235.5%) | -$87.22 M(+209.8%) |
| June 2020 | - | -$14.41 M(-30.9%) | -$28.15 M(-580.5%) |
| Mar 2020 | - | -$20.87 M(+480.8%) | $5.86 M(-88.3%) |
| Dec 2019 | - | -$3.59 M(-133.5%) | $49.91 M(-23.9%) |
| Sept 2019 | $65.63 M(-228.1%) | $10.72 M(-45.3%) | $65.63 M(+45.9%) |
| June 2019 | - | $19.60 M(-15.5%) | $44.97 M(+323.2%) |
| Mar 2019 | - | $23.19 M(+91.3%) | $10.63 M(-140.2%) |
| Dec 2018 | - | $12.12 M(-222.0%) | -$26.44 M(-48.4%) |
| Sept 2018 | -$51.24 M(+58.6%) | -$9.94 M(-32.6%) | -$51.24 M(+1.7%) |
| June 2018 | - | -$14.74 M(+6.2%) | -$50.39 M(+25.4%) |
| Mar 2018 | - | -$13.88 M(+9.5%) | -$40.20 M(+28.6%) |
| Dec 2017 | - | -$12.67 M(+39.3%) | -$31.26 M(-3.2%) |
| Sept 2017 | -$32.31 M(-57.7%) | -$9.10 M(+99.8%) | -$32.31 M(-23.3%) |
| June 2017 | - | -$4.55 M(-7.9%) | -$42.11 M(-24.9%) |
| Mar 2017 | - | -$4.94 M(-64.0%) | -$56.08 M(-21.7%) |
| Dec 2016 | - | -$13.72 M(-27.4%) | -$71.60 M(-6.3%) |
| Sept 2016 | -$76.43 M(-18.4%) | -$18.90 M(+2.0%) | -$76.43 M(-6.7%) |
| June 2016 | - | -$18.52 M(-9.5%) | -$81.91 M(+4.2%) |
| Mar 2016 | - | -$20.46 M(+10.3%) | -$78.63 M(-10.0%) |
| Dec 2015 | - | -$18.55 M(-23.9%) | -$87.36 M(-6.7%) |
| Sept 2015 | -$93.64 M(+88.2%) | -$24.37 M(+59.8%) | -$93.64 M(+5.0%) |
| June 2015 | - | -$15.25 M(-47.7%) | -$89.17 M(+3.3%) |
| Mar 2015 | - | -$29.18 M(+17.6%) | -$86.34 M(+27.0%) |
| Dec 2014 | - | -$24.83 M(+24.7%) | -$67.98 M(+36.6%) |
| Sept 2014 | -$49.76 M(+131.1%) | -$19.91 M(+60.3%) | -$49.76 M(+32.9%) |
| June 2014 | - | -$12.42 M(+14.9%) | -$37.45 M(+26.3%) |
| Mar 2014 | - | -$10.82 M(+63.7%) | -$29.65 M(+24.7%) |
| Dec 2013 | - | -$6.61 M(-13.1%) | -$23.78 M(+10.4%) |
| Sept 2013 | -$21.53 M(+11.3%) | -$7.60 M(+64.2%) | -$21.53 M(+14.1%) |
| June 2013 | - | -$4.63 M(-6.4%) | -$18.86 M(-8.5%) |
| Mar 2013 | - | -$4.94 M(+13.3%) | -$20.61 M(+2.5%) |
| Dec 2012 | - | -$4.36 M(-11.6%) | -$20.12 M(+4.0%) |
| Sept 2012 | -$19.34 M | -$4.93 M(-22.7%) | -$19.34 M(+12.1%) |
| June 2012 | - | -$6.38 M(+43.5%) | -$17.26 M(+37.2%) |
| Mar 2012 | - | -$4.44 M(+24.0%) | -$12.58 M(+27.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | - | -$3.58 M(+25.9%) | -$9.88 M(+3.3%) |
| Sept 2011 | -$9.56 M(+72.1%) | -$2.85 M(+67.2%) | -$9.56 M(+13.4%) |
| June 2011 | - | -$1.70 M(-2.3%) | -$8.43 M(+4.7%) |
| Mar 2011 | - | -$1.74 M(-46.6%) | -$8.05 M(+120.5%) |
| Dec 2010 | - | -$3.27 M(+90.3%) | -$3.65 M(+54.1%) |
| Sept 2010 | -$5.56 M(-70.1%) | -$1.72 M(+29.8%) | -$2.37 M(-39.8%) |
| June 2010 | - | -$1.32 M(-149.8%) | -$3.94 M(-15.4%) |
| Mar 2010 | - | $2.66 M(-233.7%) | -$4.65 M(-62.1%) |
| Dec 2009 | - | -$1.99 M(-39.5%) | -$12.26 M(-34.0%) |
| Sept 2009 | -$18.57 M(-45.2%) | -$3.28 M(+61.0%) | -$18.57 M(-30.1%) |
| June 2009 | - | -$2.04 M(-58.8%) | -$26.56 M(-22.2%) |
| Mar 2009 | - | -$4.95 M(-40.2%) | -$34.15 M(-5.1%) |
| Dec 2008 | - | -$8.29 M(-26.5%) | -$35.97 M(+4.9%) |
| Sept 2008 | -$33.87 M(-8.3%) | -$11.28 M(+17.1%) | -$34.28 M(-0.2%) |
| June 2008 | - | -$9.63 M(+42.1%) | -$34.36 M(-9.3%) |
| Mar 2008 | - | -$6.78 M(+2.7%) | -$37.88 M(-3.6%) |
| Dec 2007 | - | -$6.60 M(-41.9%) | -$39.30 M(+6.4%) |
| Sept 2007 | -$36.95 M(+88.5%) | -$11.36 M(-13.6%) | -$36.95 M(+18.4%) |
| June 2007 | - | -$13.14 M(+60.3%) | -$31.19 M(+39.6%) |
| Mar 2007 | - | -$8.20 M(+93.3%) | -$22.34 M(+12.3%) |
| Dec 2006 | - | -$4.24 M(-24.2%) | -$19.89 M(+1.8%) |
| Sept 2006 | -$19.60 M(+119.0%) | -$5.60 M(+30.5%) | -$19.54 M(+13.9%) |
| June 2006 | - | -$4.29 M(-25.4%) | -$17.15 M(+10.6%) |
| Mar 2006 | - | -$5.76 M(+48.2%) | -$15.51 M(+37.6%) |
| Dec 2005 | - | -$3.88 M(+20.8%) | -$11.27 M(+25.8%) |
| Sept 2005 | -$8.95 M(+242.1%) | -$3.21 M(+21.1%) | -$8.96 M(+26.3%) |
| June 2005 | - | -$2.65 M(+74.6%) | -$7.09 M(+40.9%) |
| Mar 2005 | - | -$1.52 M(-3.2%) | -$5.03 M(+24.5%) |
| Dec 2004 | - | -$1.57 M(+16.5%) | -$4.04 M(+54.6%) |
| Sept 2004 | -$2.62 M(+2674.2%) | -$1.35 M(+126.7%) | -$2.62 M(+103.5%) |
| June 2004 | - | -$594.30 K(+11.9%) | -$1.29 M(+82.5%) |
| Mar 2004 | - | -$531.10 K(+273.2%) | -$704.40 K(+250.3%) |
| Dec 2003 | - | -$142.30 K(+708.5%) | -$201.10 K(+124.9%) |
| Sept 2003 | -$94.30 K(-93.3%) | -$17.60 K(+31.3%) | -$89.40 K(-93.6%) |
| June 2003 | - | -$13.40 K(-51.8%) | -$1.39 M(-2.2%) |
| Mar 2003 | - | -$27.80 K(-9.2%) | -$1.42 M(+0.4%) |
| Dec 2002 | - | -$30.60 K(-97.7%) | -$1.41 M(+0.3%) |
| Sept 2002 | -$1.41 M(+1270.1%) | -$1.32 M(+2895.9%) | -$1.41 M(+1054.4%) |
| June 2002 | - | -$43.90 K(+96.0%) | -$121.90 K(+30.4%) |
| Mar 2002 | - | -$22.40 K(-12.8%) | -$93.50 K(-1.5%) |
| Dec 2001 | - | -$25.70 K(-14.0%) | -$94.90 K(-7.1%) |
| Sept 2001 | -$102.70 K(+1.1%) | -$29.90 K(+92.9%) | -$102.20 K(+3.8%) |
| June 2001 | - | -$15.50 K(-34.9%) | -$98.50 K(-5.4%) |
| Mar 2001 | - | -$23.80 K(-27.9%) | -$104.10 K(+0.4%) |
| Dec 2000 | - | -$33.00 K(+26.0%) | -$103.70 K(+2.1%) |
| Sept 2000 | -$101.60 K(+111.2%) | -$26.20 K(+24.2%) | -$101.60 K(+34.7%) |
| June 2000 | - | -$21.10 K(-9.8%) | -$75.40 K(+38.9%) |
| Mar 2000 | - | -$23.40 K(-24.3%) | -$54.30 K(+75.7%) |
| Dec 1999 | - | -$30.90 K | -$30.90 K |
| Sept 1999 | -$48.10 K(+218.5%) | - | - |
| Sept 1998 | -$15.10 K(-72.4%) | - | - |
| Sept 1997 | -$54.80 K | - | - |
FAQ
- What is Arrowhead Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals annual EBITDA year-on-year change?
- What is Arrowhead Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Arrowhead Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Arrowhead Pharmaceuticals?
- What is Arrowhead Pharmaceuticals TTM EBITDA year-on-year change?
What is Arrowhead Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ARWR is -$561.51 M
What is the all time high annual EBITDA for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $65.63 M
What is Arrowhead Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, ARWR annual earnings before interest, taxes, depreciation & amortization has changed by -$385.84 M (-219.64%)
What is Arrowhead Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ARWR is -$153.13 M
What is the all time high quarterly EBITDA for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $55.40 M
What is Arrowhead Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, ARWR quarterly earnings before interest, taxes, depreciation & amortization has changed by -$24.07 M (-18.65%)
What is Arrowhead Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ARWR is -$561.51 M
What is the all time high TTM EBITDA for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $65.63 M
What is Arrowhead Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, ARWR TTM earnings before interest, taxes, depreciation & amortization has changed by -$293.04 M (-109.15%)